Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease

Grants

Funding Acknowledgements

Funding from the National Health and Medical Research Council (R.C., A.R.W.), the University of Sydney (R.C., J.L.), and Parkinson's NSW (R.C., A.R.W.) is gratefully acknowledged. The authors kindly thank Dr. Janetta Culvenor, University of Melbourne, for provision of the alpha-synuclein antibody.